Citation: | WU Tao, WANG Xiumei, ZHU Liping, FU Lati, OU Jianghua, NI Duo. Analysis on Related Factors of Bone Mineral Density Reduction in Postmenopausal Women with Early Breast Cancer One Year after Surgery[J]. Cancer Research on Prevention and Treatment, 2013, 40(10): 966-968. DOI: 10.3971/j.issn.1000-8578.2013.10.012 |
[1] |
Abdel-Razeq H, Awidi A. Bone health in breast cancer survivors[J]. J Cancer Res Ther, 2011,7(3): 256-63.
|
[2] |
Bryce J, Bauer M, Hadji P. Aromatase inhibitor-associated bone loss[J]. Oncol Nurs Forum, 2011, 38(3): 273-6.
|
[3] |
Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment[J]. Ann Oncol, 2011, 22(12): 2546-55.
|
[4] |
Dawson-Huqhes B, Looker AC, Tosteson AN, et al. The potential impact of the national osteoporosis foundation guidance on treatment eligibility in the usa: an update in NHANES 2005-2008[J]. Osteoporos Int, 2012, 23(3): 811-20.
|
[5] |
Liu ZH,Zhu HM,Yang DZ,et al. Recommendations of the diagnostic criteria for osteoporosis in chinese(2nd draft)[J]. Zhongguo Gu Zhi Shu Song Za Zhi,2000,6(1):1-3. [刘忠 厚,朱汉民,杨定焯,等.中国人骨质疏松症建议诊断标准 (第二稿)[J].中国骨质疏松杂志,2000,6(1):1-3.
|
[6] |
Lester JE, Dodwell D, Horsman JM, et al. Current management of treatment-induced bone loss in women with breast cancer treated in the united kingdom[J]. Br J Cancer, 2006, 94(1):30-5.
|
[7] |
Geisler J, Lønning PE. Aromatase inhibitors as adjuvant treatment of breast cancer[J]. Crit Rev Oncol Hematol, 2006, 57(1): 53-61.
|
[8] |
Jin H, Tu D, Zhao N, et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover[J]. J Clin Oncol, 2012, 30(7): 718-21.
|
[9] |
Lønning PE. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?[J]. Anticancer Drugs, 2008, 19 Suppl 2:S11-3.
|
[10] |
Lester JE, Dodwell D, Purohit OP, et al.Prevention of anastrozoleinduced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer[J]. Clin Cancer Res, 2008, 14(19): 6336-42.
|
[11] |
Coleman R, Cook R, Hirsh V, et al. Zoledronic acid use in cancer patients: more than just supportive care?[J]. Cancer, 2011, 117(1): 11-23.
|
[12] |
Kim JE, Ahn JH, Jung KH, et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the korean cancer study group (KCSG-BR06-01)[J]. Breast Cancer Res Treat, 125(1): 99-106.
|